Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Functional Classification of Joints01:09

Functional Classification of Joints

Functional Classification of Joints
The functional classification of joints is determined by the amount of mobility between the adjacent bones. Joints are functionally classified as a synarthrosis or immobile joint, an amphiarthrosis or slightly moveable joint, or as a diarthrosis, a freely moveable joint. Fibrous and cartilaginous joints can be functionally classified as either synarthroses  or amphiarthroses, whereas all synovial joints are classified as diarthroses.
Synarthrosis
An immobile...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Structural Joints: Cartilaginous Joints01:17

Structural Joints: Cartilaginous Joints

As the name indicates, at a cartilaginous joint, the adjacent bones are united by cartilage, a tough but flexible type of connective tissue. Unlike synovial joints, these types of joints lack a joint cavity and involve bones joined together by either hyaline cartilage or fibrocartilage.
There are two types of cartilaginous joints:
Synchondrosis
A synchondrosis ("joined by cartilage") is a cartilaginous joint where bones are connected by hyaline cartilage. Synchondrosis may be temporary or...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Responsiveness of spondyloarthritis-specific health utilities based on the ASAS Health Index (U-ASAS-HI): an ancillary analysis from the ASAS-HI validation study.

Rheumatology (Oxford, England)·2025
Same author

Response to the correspondence on "Radiographic structural damage in axial spondyloarthritis: is there a preferred way to quantify progression over time?"

Annals of the rheumatic diseases·2025
Same author

Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets.

Rheumatology (Oxford, England)·2025
Same author

Radiographic structural damage in axial spondyloarthritis: is there a preferred way to quantify progression over time? Comparison of blinded versus unblinded mSASSS scoring.

Annals of the rheumatic diseases·2025
Same author

Prevalence and associations of kinesiophobia with patient reported outcomes and mobility measures in axial spondyloarthritis.

Joint bone spine·2025
Same author

Why the term nr-axSpA should not be used for diagnosis.

Annals of the rheumatic diseases·2025

Related Experiment Video

Updated: May 25, 2026

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
04:47

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Published on: October 27, 2023

Spondyloarthritides.

Xenofon Baraliakos1, Juergen Braun

  • 1Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany. baraliakos@me.com

Best Practice & Research. Clinical Rheumatology
|January 24, 2012
PubMed
Summary
This summary is machine-generated.

Spondyloarthropathies (SpA) encompass inflammatory back pain, peripheral, and extra-articular symptoms. While NSAIDs and physiotherapy are first-line treatments, anti-tumour necrosis factor (TNF) agents offer options for refractory cases.

More Related Videos

Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis
06:23

Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis

Published on: May 23, 2021

Related Experiment Videos

Last Updated: May 25, 2026

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
04:47

Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis

Published on: October 27, 2023

Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis
06:23

Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis

Published on: May 23, 2021

Area of Science:

  • Rheumatology and Immunology
  • Clinical Medicine

Background:

  • Spondyloarthropathies (SpA) present with diverse clinical features including inflammatory back pain (IBP), peripheral joint involvement (enthesitis), and extra-articular manifestations.
  • SpA comprises axial and peripheral forms, with subgroups like ankylosing spondylitis (AS), psoriatic arthritis, and inflammatory bowel disease (IBD)-associated SpA.
  • The prevalence of SpA is comparable to rheumatoid arthritis, and disease outcomes are influenced by disease activity, inflammation, and structural damage such as new bone formation.

Purpose of the Study:

  • To review the clinical features, classification, and current treatment strategies for spondyloarthropathies (SpA).
  • To highlight the role of conventional therapies and emerging biologic treatments for SpA management.
  • To discuss the impact of disease activity and structural damage on patient outcomes.

Main Methods:

  • Literature review of clinical features, diagnostic criteria, and therapeutic interventions for SpA.
  • Analysis of treatment efficacy for non-steroidal anti-inflammatory drugs (NSAIDs), physiotherapy, and anti-tumour necrosis factor (TNF) agents.
  • Evaluation of factors influencing disease progression, including inflammation and new bone formation.

Main Results:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) are effective for inflammatory back pain (IBP) in SpA.
  • Physiotherapy is crucial for maintaining spinal mobility in ankylosing spondylitis (AS).
  • Anti-tumour necrosis factor (TNF) inhibitors are approved for active AS patients unresponsive to conventional therapy, though their effect on new bone formation is unclear.

Conclusions:

  • SpA management requires a comprehensive approach addressing various clinical manifestations.
  • Early and appropriate treatment, including NSAIDs, physiotherapy, and biologics like anti-TNF agents, is essential for improving SpA outcomes.
  • Further research is needed to understand the long-term impact of treatments on structural damage, particularly new bone formation in AS.